RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Monoclonal Antibody Reduces LDL-C in Presence of Statin (LAPLACE-2)
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 4
SP 15
OP 16
DO 10.1177/155989771404005
UL http://mdc.sagepub.com/content/14/4/15.abstract
AB The monoclonal antibody evolocumab (previously AMG 145), which inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), dramatically lowered levels of low-density lipoprotein cholesterol (LDL-C) in Phase 2 clinical trials when administered alone or in combination with a statin, including among patients intolerant of statin therapy, those with familial hypercholesterolemia, and in those treated in a 52-week study [Koren MJ et al. Circulation 2013; Giugliano RP et al. Lancet 2012; Koren MJ et al. Lancet 2012; Raal F et al. Circulation 2012; Sullivan D et al. JAMA 2012]. This article discusses the Phase 3 LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 study [LAPLACE-2; NCT01763866].